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Extracellular High-Mobility Group Box 1 is Increased in Patients 
with Behçet’s Disease with Intestinal Involvement
High-mobility group box 1 (HMGB1) protein has been demonstrated to play an important 
role in chronic inflammatory diseases including rheumatoid arthritis, and systemic lupus 
erythematosus. This study investigated the association between extracellular HMGB1 
expression and disease activity, and clinical features of Behçet’s disease (BD). Extracellular 
HMGB1 expression in the sera of 42 BD patients was measured and was compared to that 
of 22 age- and sex-matched healthy controls. HMGB1 expression was significantly 
increased in BD patients compared to healthy controls (78.70 ± 20.22 vs 10.79 ± 1.90 ng/
mL, P = 0.002). In addition, HMGB1 expression was significantly elevated in BD patients 
with intestinal involvement compared to those without (179.61 ± 67.95 vs 61.89 ± 19.81 
ng/mL, P = 0.04). No significant association was observed between HMGB1 concentration 
and other clinical manifestations, or disease activity. It is suggested that extracellular 
HMGB1 may play an important role in the pathogenesis of BD.
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BRIEF COMMUNICATION
Immunology, Allergic Disorders & Rheumatology
Behçet’s disease (BD) is a chronic multisystemic inflammatory 
disorder of unknown etiology, consisting of orogenital ulceration, 
ocular inflammation, intestinal involvement and skin lesions (1, 
2). The innate immune system is involved in BD pathogenesis 
as evidenced by frequent mucocutaneous symptoms, Toll-like 
receptor (TLR) expression in affected cells, and neutrophil hy-
per-responsiveness to Streptococcus sanguis antigens and heat 
shock proteins (HSPs) (1, 3, 4). 
  High-mobility group box 1 (HMGB1) protein functions to 
stabilize nucleosome formation and also acts as a transcription-
factor-like protein. It is an important damage-associated molec-
ular pattern molecules (DAMPs), along with HSPs and S100 pro-
tein (5). HMGB1 is a crucial cytokine that mediates the response 
to infection and inflammation. It activates macrophages and 
monocytes to release proinflammatory cytokines, upregulates 
endothelial adhesion molecules, and stimulates epithelial cell 
barrier failure (5, 6). HMGB1 is released from necrotic cells and 
secreted from activated macrophages, dendritic cells, and natu-
ral killer cells. It has an important function in chronic inflam-
matory diseases including rheumatoid arthritis, systemic lupus 
erythematosus, and inflammatory myositis (6-11). 
  Innate immunity has been investigated as a critical step in 
initiating and aggravating inflammation in BD. HMGB1 is known 
as a potent stimulator of the innate immune system and medi-
ates the immune process between innate and adaptive immu-
nity (12). The expression of HMGB1 and its affect on BD, how-
ever, are currently not known. Thus, the aim of this study was to 
investigate the extracellular HMGB1 expression in BD, and the 
association between extracellular HMGB1 expression and dis-
ease activity, and clinical features of BD. 
  The experimental protocols used in this study were approved 
by the local ethics committee and informed consent was ob-
tained from each patient. Forty-two patients with BD fulfilled 
the diagnostic criteria of the International BD Study Group (13). 
The control group consisted of 22 healthy age- and sex-matched 
volunteers with no history of autoimmune diseases or signifi-
cant severe infection at the time of sampling. For all study pa-
tients enrolled, the following demographic and clinical data were 
obtained from medical records: age at the time of diagnosis of 
BD, sex, duration of disease, clinical signs and symptoms, and 
laboratory data including neutrophil count, erythrocyte sedi-
mentation rate (ESR), and C-reactive protein (CRP). Both clini-
cal and laboratory findings were used to classify active and in-
active BD patients. Active disease patients were defined as those 
with worsening clinical symptoms at the time of study visit in 
addition to at least three of the following major findings: oral ul-Ahn JK, et al.  •  Extracellular HMGB1 in Behçet’s Disease
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cerations or stomatitis; genital ulcers; anterior iridocyclitis, pos-
terior vasculitis or panuveitis; cutaneous findings; or positive 
pathergy test (14). Ethylenediaminetetraacetate serum samples 
of BD patients and healthy controls were centrifuged at 1,500 g 
for 10 min and the supernatants were stored at -20°C until use. 
HMGB1 levels in the serum were quantified using a commer-
cially available ELISA Kit, according to the manufacturer’s in-
structions (IBL international GMBH, Hamburg, Germany). In 
statistical analysis, data are expressed as means and standard 
error of mean (SEM) and as percentages, unless otherwise indi-
cated. The normality of data was tested by Shapiro-Wilk test. To 
compare continuous variable distributions and categorical vari-
ables between groups, we used Student’s t-test or Mann-Whitney 
U test and the chi-squared-test or Fisher’s Exact test, respective-
ly. Correlations between groups were determined using Spear-
man’s rank correlation analysis. Differences were considered 
significant at P < 0.05 level. The PASW statistics software pack-
age (version 17.0, SPSS Institute, Chicago, IL, USA) was used for 
all analyses. 
  The 42 BD patients contained 25 active and 17 inactive pa-
tients with a mean age of 47 yr (range 22-65 yr). The 22 healthy 
controls were 10 males and 12 females with a mean age of 43 yr 
(range 28-67 yr). No differences were seen in gender and age 
between the 42 patients and the 22 healthy controls. In BD group, 
skin lesions (81.0%), including erythema nodosum, were the 
second most common clinical finding, followed by genital ul-
ceration (73.8%), arthritis (45.2%), vascular involvement (28.6%), 
ocular lesions (19%), and intestinal lesions (14.3%). No patients 
showed central nervous system involvement. 
  As shown in Fig. 1A, the extracellular HMGB1 concentration 
in serum samples of BD patients and healthy controls as mea-
sured by ELISA were 78.70 ± 20.22 ng/mL and 10.79 ± 1.90 ng/
mL, respectively (P = 0.002). Next, we measured extracellular 
HMGB1 expression in the serum of 25 active and 17 inactive 
patients. The extracellular HMGB1 expression was higher in ac-
tive patients than inactive patients (92.26 ± 31.63 vs 58.78 ± 18.46 
ng/mL), although this difference did not reach statistical signif-
icance (P = 0.367, Fig. 1B). 
  We evaluated the difference in extracellular HMGB1 expres-
sion by the presence of clinical features in BD patients (Table 1). 
Patients with intestinal involvement had a higher mean extra-
cellular HMGB1 expression than those without intestinal symp-
tom (179.61 ± 67.95 vs 61.89 ± 19.81 ng/mL, P = 0.04). Patients 
with vascular involvement showed a trend toward decreased 
serum HMGB1 expression compared to those without, but did 
not reach statistical significance (36.79 ± 12.63 vs 95.47 ± 27.41 
ng/mL, P = 0.059). No significant association was observed be-
tween extracellular HMGB1 concentration and other clinical 
manifestations, including genital ulcer, erythema nodosum, oc-
ular involvement or musculoskeletal symptoms. No significant 
correlation was found between HMGB1 concentration and leu-
kocyte counts, ESR, or CRP (r = -0.248, P = 0.113; r = -0.010, P = 
0.951; r = -0.104, P = 0.514). 
  The innate immune system and neutrophil hyper-responsive-
Table 1. Difference in extracellular HMGB1 concentration according to the presence 
of each clinical feature in patients with Behçet’s disease
Clinical features  HMGB1 (ng/mL)  P value  
Genital ulcer 
   (-) 
   (+) 
 
68.32 ± 28.15 
82.39 ± 25.73 
0.764 
EN-like lesions
   (-) 
   (+) 
 
90.02 ± 33.21 
68.42 ± 24.63 
0.600 
Pathergy test
   (-) 
   (+) 
 
85.57 ± 30.55 
43.85 ± 23.85 
0.307 
Vascular lesion
   (-) 
   (+) 
 
95.47 ± 27.41 
36.79 ± 12.63 
0.059 
Ocular lesion
   (-) 
   (+) 
 
86.03 ± 24.47 
47.57 ± 20.11 
0.462
Articular lesion
   (-) 
   (+) 
 
75.40 ± 22.51 
82.71 ± 36.16 
0.860 
Skin lesions
   (-) 
   (+) 
 
82.08 ± 25.23 
75.00 ± 32.84 
0.864
Intestinal lesion
   (-) 
   (+) 
 
61.89 ± 19.81 
179.61 ± 67.95 
0.040
Unless otherwise indicated, values are frequency (percentage) or mean ± standard 
error mean. EN, erythema nodosum. 
Fig. 1. Comparison of extracellular HMGB1 levels between BD patients and healthy controls (A), and between active and inactive BD groups (B).
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ness are involved in BD pathogenesis (1, 3, 4). HMGB1 is a well-
characterized DAMP, like the defensins, and functions in the 
innate immune system. As a cytokine, HMGB1 activates endo-
thelial cell, promotes angiogenesis, enhances hematopoietic 
stem-cell migration, and initiates inflammation (5). We found 
that the mean extracellular HMGB1 expression is increased 
seven-to-eight-fold in BD patients compared to healthy controls. 
Extracellular HMGB1 enhances the expression of pro-inflam-
matory cytokines such as TNF-α, IL-6 and IFN-γ through the NF-
κB pathway in human neutrophils (15), and neutrophils are crit-
ical for mediating BD development. Many studies found an in-
crease in pro-inflammatory cytokines such as IL-1, IL-8, IL-12, 
IL-15, and TNF-α in the sera of BD patients (16). Considering 
these findings and our results, these pro-inflammatory effects 
of extracellular HMGB1 are likely to be involved in various clini-
cal manifestations of BD. 
  We demonstrated that HMGB1 concentration was significant-
ly elevated in patients with intestinal involvement compared to 
those without intestinal involvement. Sappington et al. reported 
that both HMGB1 and B box proteins increased the permeabil-
ity of human enterocytic cell lines in a time- and concentration-
dependent manner. Administration of HMGB1 B box to wild-
type mice increases ileal mucosal permeability, and HMGB1 or 
B box induces increased nitric oxide (NO) production and in-
creased induction of NO synthase mRNA (17). Extracellular 
HMGB1 increased production of TNF-α and IFN-γ (5, 15, 18). 
Thus, extracellular HMGB1 may influence development and 
aggravation of intestinal lesion of BD through increased NO and 
pro-inflammatory cytokine production and induction of NO 
synthase expression.
  HMGB1 activates endothelial cells, leading to increased ex-
pression of adhesion molecules such as intracellular adhesion 
molecule 1 and vascular cell-adhesion molecule 1 (19). This rais-
es the possibility that HMGB1 is involved in the vascular injury 
of BD. Orogenital ulcerations, and erythema-nodosum-like le-
sions are examples of direct injury to the vessel wall. However, no 
differences in extracellular HMGB1 levels were seen with geni-
tal ulcerations, erythema nodosum-like lesion, or vascular in-
volvement. Unexpectedly, although this finding was not signifi-
cant, patients without vascular involvement showed higher levels 
of extracellular HMGB1 compared to those with this symptom. 
The number of investigated patients with BD might be small for 
this conclusive result. Therefore, the role of extracellular HMGB1 
in vascular manifestation of BD warrants further investigation. 
  No serological marker in assessing disease activity is available 
in BD. Many researchers have attempted to identify specific se-
rologic markers to predict disease activity or prognosis. Recent-
ly, it has been reported that a soluble triggering receptor expressed 
on myeloid cells-1 (sTREM-1) in BD patients with intestinal in-
volvement was significantly higher than those in healthy con-
trols, suggesting possible role of serum sTREM-1 level as a po-
tential marker for disease activity of intestinal BD (20). The as-
sociations of HMGB1 level with intestinal involvement and pos-
sibly vascular involvement in the present study further suggest 
that HMGB1 may be utilized as a valuable serological marker of 
the severity of inflammation. Further studies will focus on the 
role of extracellular HMGB1 as the inflammatory marker poten-
tially reflecting disease activity of BD. 
  This is the first study to evaluate the expression of HMGB1 in 
BD. An important finding is that extracellular HMGB1 expres-
sion is significantly increased in BD patients compared to healthy 
controls, and is significantly increased in the sera of BD patients 
with intestinal involvement compared to those without intesti-
nal involvement. It is suggested that extracellular HMGB1 may 
play an important role in the pathogenesis of BD. Further stud-
ies are needed to elucidate the extracellular HMGB 1 as a poten-
tial therapeutic target in the treatment of intestinal BD.
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